The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Sumarokov A.B.

National Medical Research Centre of Cardiology

Non-compliance with treatment in patients with hyperlipidemia as a risk factor of cardiovascular disease

Authors:

Sumarokov A.B.

More about the authors

Journal: Russian Cardiology Bulletin. 2021;16(1): 28‑33

DOI: 10.17116/Cardiobulletin20211601128

Read: 1476 times

Download PDF (RU)
Contact the author
Table of contents

NON-COMPLIANCE WITH TREATMENT IN PATIENTS WITH HYPERLIPIDEMIA AS A RISK FACTOR OF CARDIOVASCULAR DISEASE
NON-COMPLIANCE WITH TREATMENT IN PATIENTS WITH HYPERLIPIDEMIA AS A RISK FACTOR OF CARDIOVASCULAR DISEASE

To cite this article:

Sumarokov AB. Non-compliance with treatment in patients with hyperlipidemia as a risk factor of cardiovascular disease. Russian Cardiology Bulletin. 2021;16(1):28‑33. (In Russ.)
https://doi.org/10.17116/Cardiobulletin20211601128

Подписка 2026 Кардиологический вестник (Russian Cardiology Bulletin)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Non-compliance with treatment (partial or complete) is a common problem in patients with chronic diseases requiring invariable treatment. Non-compliance is often observed in lipid lowering therapy. Certain factors related to non-compliance in lipid lowering therapy are discussed in the manuscript. There are data on higher risk of serious cardiovascular events in non-compliant patients.

Keywords:

cardiovascular diseases
atherosclerosis
lipid lowering therapy
non-compliance with treatment

Authors:

Sumarokov A.B.

National Medical Research Centre of Cardiology

Received:

14.12.2020

Accepted:

08.02.2021

Close metadata

References:

  1. Nikolaev NA, Martynov AI, Skirdenko IuP, Anisimov VN, Vasil`eva IA, Vinogradov OI, Lazebnic LB, Poddubnaya IV, Roitman EV, Ershov AV. Management of treatment on the basis of adherence. Consensus document — Clinical recommendations. Consilium Medicum. 2020;22(5):9-18. (In Russ.).
  2. Blackburn DF, Dobson RT, Blackburn JL, Wilson TW. Cardiovascular morbidity associated with nonadherence to statin therapy. Pharmacotherapy. 2005;25(8):1035-1043. https://doi.org/10.1592/phco.2005.25.8.1035
  3. De Vera MA, Bhole V, Burns LC, Lacaille D. Impact of statin adherence on cfrdiovascular disease and mortality outcomes: a systematic review. British Journal of Clinical Pharmacology. 2014;78(4):684-698.  https://doi.org/10.1111/bcp.12339
  4. Deichmann RE, Morledge MD, Ulep R, Shaffer JP, Davies P, van Driel ML. A metaanalysis of Interventions to Improve Adherence to Lipid-Lowering Medication. Ochsner Journal. 2016;16(3):230-237. 
  5. Danilov DS. Therapeutic collaboration (compliance): Content of definition, mechanism of formation, and methods of optimization. Nevrologiya, nejropsihiatriya, psihosomatika. 2014;2:4-12. (In Russ.). https://doi.org/10.14412/2074-2711-2014-2-4-12
  6. Lukina YV, Kutishenko NP, Martsevich SY. The Problem of Adherence to the Treatment in Modern Medicine: Possibilities of Solution, Impact on the Effectiveness of Therapy and Disease Outcomes. Racional’naya farmakoterapiya v kardiologii. 2017;13(4):519-524. (In Russ.). https://doi.org/10.20996/1819-6446-2017-13-4-519-524
  7. Casula M, Tragni E, Catapano AL. Adherence to lipid-lowering treatment: the patient perspective. Patient Preference and Adherence. 2012;6:805-814.  https://doi.org/10.2147/PPA.S29092
  8. Tolpygina SN, Polyanskaya YuN, Martsevich SYu. Hypolipidemic therapy in patients with chronic ischemic heart disease in 2004—2010 according to the PROGNOZ IBS register. Racional’naya farmakologiya v kardiologii. 2015;11(2):153-158. (In Russ.).
  9. Lukina YuV, Martsevich SYu, Zagrebelnyy AV, Tripkosh SG, Aidu FA, Deev AD. Therapeutic compliance in ambulatory patients: PROFILE Register data. Kardiovaskulyarnaya terapiya i profilaktika. 2013;12(5):56-61. (In  uss.).
  10. Huber D, Christiansen W, Henriksson R, Soderstrem L, Mooe T. Statin treatment after acute coronary syndrome: Adherence and reasons for non-adherence in a randomized controlled intervention trial. Scientific Reports. 2019;9(1):12079. https://doi.org/10.1038/s41598-019-48540-3
  11. Moriski DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a Medication Adherence Measure in an Outpatient Setting. Journal of Clinical Hypertension. 2008;10(5):348-354.  https://doi.org/10.1111/j.1751-7176.2008.07572.x
  12. Martsevich SYu, Lukina YuV, Kutishenko NP, Dmitrieva NA, Blagodatskich SV, Lerman OV, Gomova TA, Drozdetsky SN, Skibitsky VV, Kudryashov EA, Puchinyan NF on behalf of working group of the observational study PRIORITY. Adherence to statins therapy of high and very high cardiovascular risk patients in real clinical practice: diagnostics and possible ways to solve the problem (according to the PRIORITY observational study). Racional’naya farmakologiya v kardiologii. 2018;14(6):891-890. (In Russ.). https://doi.org/10.20996/1819-6446-2018-14-6-891-900
  13. Nikolaev NA, Skirdenko YuP. Russian universal questionary adherence to treatment (KOP25). Klinicheskaya farmakologiya i terapiya. 2018;27(1):74-78. (In Russ.).
  14. Ofori-Asenso R, Jakhu A, Curtis AJ, Zomer E, Gambhir M, Korhonen MJ, Nelson M, Tonkin A, Liew D, Zoungas S. A Systematic Review and Meta-Analysis of the Factors Associated with Nonadherence and Discontinuation of Statins among People >65 years. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2018;73(6):798-805.  https://doi.org/10.1093/gerona/glx256
  15. Ofori-Asenso R, Ilomaki J, Tacey M, Curtis AJ, Zomer E, Bell JS, Zoungas S, Liew D. Predictors of first-year nonadherence and discontinuation of statins among older adults: a retrospective cohort study. British Journal of Clinical Pharmacology. 2019;85(1):227-235.  https://doi.org/10.1111/bcp.13797
  16. Martsevich SY, Gaysenok OV, Tripkosh SG, Zagrebelnyy AV, Lukina YV. Medical supervision in specialized center and quality of lipid-lowering therapy in patients with cardiovascular diseases (according to the PROFIL register). Racional’naya farmakologiya v kardiologii. 2013;9(2):133-137. (In Russ.). https://doi.org/10.20996/1819-6446-2013-9-2-133-137
  17. Fofanova TV, Ageev FT, Smirnova MD, Svirida ON, Kuzmina AE, Thostov ASh, Nelyubina AS. National questianary of treatment compliance testing in outpatient practice. Sistemnye gipertenzii. 2014;2:13-16. (In Russ.).
  18. Toth P, Granovitz C, Hull M, Anderson A, Philip S. Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis. Lipids in Health and Disease. 2019;18(1):175.  https://doi.org/10.1186/s12944-019-1099-z
  19. Colantonio LD, Rosenson RS, Deng L, Monda KL, Dai Y, Farkouh ME, Safford MM, Philip K, Mues KE, Muntner P. Adherence to Statin Therapy among US Adults Between 2007 and 2014. Journal of the American Heart Association. 2019;8(1):e010376. https://doi.org/10.1161/JAHA.118.010376
  20. Dopheide J, Veit J, Ramadani H, Adam L, Papac L, Schindewolf M, Vonbank A, Baumgartner I, Drexel H. Adherence to Statin Therapy Drives Survival of Patients with Symptomatic Peripheral Artery Disease. European Cardiology. 2020;15:e30.  https://doi.org/10.15420/ecr.2020.15.1.PO7
  21. Karlsson SA, Hero C, Svensson A-M, Franzén S, Miftaraj M, Gudbjörnsdottir S, Eeg-Olofsson K, Eliasson B, Andersson Sundell KA. Association between refill adherence to lipid-lowering medications and the risk of cardiovascular disease and mortality in Swedish patients with type 2 diabetes mellitus: a nationwide cohort study. BMJ Open. 2018;8(3):e020309. https://doi.org/10.1136/bmjopen-2017-020309
  22. Greenland M, Knuiman MW, Hung J, Nedkoff L, Arnet I, Rankin JM, Kilkenny VF, Sanfilippo FM. Cardioprotective medication adherence in Western Australians in the first year after myocardial infarction: restricted cubuc spline analysis of adherence — outcome relationships. Scientific Reports. 2020;10(1):4315. https://doi.org/10.1038/s41598-020-60799-5
  23. Davidovich IM, Malay LN, Kutishenko NP. The analysis of long-term outcomes and adherent to treatment in patients after myocardial infarction: Khabarovsk register data. Klinicist. 2017;11(1-4):36-44. (In Russ.). https://doi.org/10.17650/1818-8338-2016-10-4-36-44
  24. Huber CA, Meyer MR, Steffel J, Blozik E, Reich O, Rosemann T. Post-myocardial Infarction (MI) Care: Medication Adherence for Secondary Prevention after MI in a Large Real-world Population. Clinical Therapeutics. 2019;41(1):107-117.  https://doi.org/10.1016/j.clinthera.2018.11.012
  25. Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid DJ, Krumholz HM, Rumsfeld JS. Impact of Medication Therapy Discontinuation on Mortality after Myocardial Infarction. Archives of Internal Medicine. 2006;166(17):1842-1847. https://doi.org/10.1001/archinte.166.17.1842
  26. Daskalopoulou SS, Doonan RJ, Delaney JA, Pilote L. Different patterns of statin use in patients with acute myocardial infarction. Current Vascular Pharmacology. 2014;12(6):885-892.  https://doi.org/10.2174/157016111206141210121017
  27. Nielsen SF, Nordesgaagd BG. Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. European Heart Journal. 2016;37(11):908-916.  https://doi.org/10.1093/eurheartj/ehv641
  28. Giral P, Neumann A, Weill A, Coste J. Cardiovascular effects of discontinuating statins for primary prevention at age of 75 years: a nationwide population-based cohort study in France. European Heart Journal. 2019;40(43):3516-3525. https://doi.org/10.1093/eurheartj/ehz458
  29. Halava H, Huupponen R, Pentti J, Kiwimaki M, Vahtera J. Predictors of first-year statin medication discontinuation: A cohort study. Journal of Clinical Lipidology. 2016;10(4):987-995.  https://doi.org/10.1016/j.jacl.2016.04.010
  30. Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association of Statin Adherence in Patients with Atherosclerotic Cardiovascular Disease. JAMA Cardiology. 2019;4(3):206-213.  https://doi.org/10.1001/jamacardio.2018.4936
  31. Cannon CP, Khan I, Klimchak AC, Sanchez RJ, Sasiela WJ, Massaro JM, D`Agostino RB, Reynolds MR. Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease. American Heart Journal. 2019;216:30-41.  https://doi.org/10.1016/j.ahj.2019.06.005
  32. Hero C, Karlsson SA, Franzen S, Svensson A-M, Mitfaraj M, Gudbjornsdottir S, Sundell KA, Eliasson B, Eeg-Olofson K. Adherence to lipid-lowering therapy and risk for cardiovascular disease and death in type 1 diabetes mellitus: a population-based study from the Swedish National Diabetes Register. BMJ Open Diabetes Research and Care. 2020;8(1):e000719. https://doi.org/10.1136/bmjdrc-2019-000719
  33. Drexel H, Coats AJS, Spoletti I, Bilato C, Mollace V, Filardi PP, Rosano GMC. An expert opinion paper on statin adherence and implementation of new lipid-lowering medication by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcome. European Heart Journal. Cardiovascular Pharmacotherapy. 2020;6(2):115-121.  https://doi.org/10.1093/ehjcvp/pvz079
  34. Kosmas C, Silverio D, Ovalle J, Montan PD, Guzman E. Patient adherence, compliance, and perspectives on evalocumab for the management of resistant hypercholesterolemia. Patient Preference and Adherence. 2018;12:2263-2266. https://doi.org/10.2147/PPA.S149423
  35. Swensson E, Nielsen RB, Hasvold P, Aaskog P, Thomsen RM. Statin prescription patterns, adherense, and atteinment of cholesterol treatment goals in routine clinical care: a Danish population — based study. Clinical Epidemiology. 2015;7:213-223.  https://doi.org/10.2147/CLEP.S78145
  36. Gragnano F, Concilio C, Cesaro A, Crispi M, Sperlongano S, Fimiani F, Natale F, Pezzulo E, Calabro R, Russo MG, Calabro P. Adherence to PCSK9 inhibitors in high cardiovascular risk patients in real-world setting: results from a single-center experience and comparison with statin therapy. European Heart Journal. 2017;38(suppl 1):314.  https://doi.org/10.1093/eurheartj/ehx502.P1513
  37. Lee M, Saver JL, Wu Y-L, Tang S-C, Lee J-D, Rao NM, Wang H-H, Jeng J-S, Lee T-H, Chen P-C, Ovbiagele B. Utilization of Statins Beyond the Initial Period after Stroke. Journal of the American Heart Association. 2017;6(8):e005658. https://doi.org/10.1161/JAHA.117.005658
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.